*Rule 3.19A.2*

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

| | |
|---|---|
| **Name of entity** | **HMC Capital Limited (ASX: HMC)** |
| **ABN** | **94 138 990 593** |

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

| | |
|---|---|
| **Name of Director** | Christopher Roberts |
| **Date of last notice** | 27 August 2026 |

**Part 1 - Change of director's relevant interests in securities**
*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Direct or indirect interest** | Direct and indirect interest |
| **Nature of indirect interest (including registered holder)**<br>Note: Provide details of the circumstances giving rise to the relevant interest. | • Romaxis Pty Ltd (ACN 126 199 924) as trustee for <Roblis Super Fund A/C> (of which Christopher Roberts is a beneficiary) (**Romaxis**)<br>• Acemed Pty Ltd (ACN 078 477 193) as trustee for <MAXIS A/C> (of which Christopher Roberts is a beneficiary) (**Acemed**) |
| **Date of change** | 19 November 2026 |
| **No. of securities held prior to change** | **Direct interest:**<br>• 21,786 fully paid ordinary shares<br><br>**Indirect interest:**<br>• Romaxis – 150,000 fully paid ordinary shares<br>• Acemed – 150,000 fully paid ordinary shares |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Class** | Rights to acquire fully paid ordinary shares |
| **Number acquired** | 19,090 rights to acquire fully paid ordinary shares |
| **Number disposed** | Nil |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and estimated valuation | Nil |
| **No. of securities held after change** | **Direct interest:**<br>• 21,786 fully paid ordinary shares<br>• 19,090 rights to acquire fully paid ordinary shares<br><br>**Indirect interest:**<br>• Romaxis – 150,000 fully paid ordinary shares<br>• Acemed – 150,000 fully paid ordinary shares |
| **Nature of change**<br>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back | Grant of rights to acquire fully paid ordinary shares in lieu of Board fees for FY27 under the Non-Executive Director Equity Plan |

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

| | |
|---|---|
| **Detail of contract** | Not applicable |
| **Nature of interest** | Not applicable |
| **Name of registered holder (if issued securities)** | Not applicable |

+ See chapter 19 for defined terms.

| | |
|---|---|
| **Date of change** | Not applicable |
| **No. and class of securities to which interest related prior to change**<br>Note: Details are only required for a contract in relation to which the interest has changed | Not applicable |
| **Interest acquired** | Not applicable |
| **Interest disposed** | Not applicable |
| **Value/Consideration**<br>Note: If consideration is non-cash, provide details and an estimated valuation | Not applicable |
| **Interest after change** | Not applicable |

## Part 3 – +Closed period

| | |
|---|---|
| **Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?** | No. |
| **If so, was prior written clearance provided to allow the trade to proceed during this period?** | Not applicable |
| **If prior written clearance was provided, on what date was this provided?** | Not applicable |

+ See chapter 19 for defined terms.